

**TRA**



**Y**

10 2003

To the Honorable Commissioner of Patent

102378709

ed original documents or copy thereof.

1. Name of conveying party(ies):

Otsuka Pharmaceutical Co., Ltd.

2-1003

- Individual(s)
- Association
- General Partnership
- Limited Partnership
- Corporation - Japan
- Other \_\_\_\_\_

Additional name(s) of conveying party(ies) attached?  Yes

No

2. Name and address of receiving party(ies):

Name: Japan Immunoresearch Laboratories, Co., Ltd.

Internal Address: \_\_\_\_\_

Street Address: 351-1 Nishiyokote-machi

City/State: Takasaki, Gunma Country: JAPAN

Individual(s) citizenship \_\_\_\_\_

Association \_\_\_\_\_

Limited Partnership \_\_\_\_\_

Corporation - State - Japan

Other \_\_\_\_\_

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No

(Designations must be a separate document from Assignment)

Additional name(s) & address(es) attached?  Yes  No

3. Nature of conveyance:

- Assignment
- Merger
- Security Agreement
- Change of Name
- Other Re-record from incorrect serial number

75/390,797 to correct serial number 75/390,737 recorded on

Reel/Frame No.: 002600/0886

Execution Date: November 12, 2001

4. Application number(s) or registration number(s):

A. Trademark Application No.(s)  
75/390737

B. Trademark Registration No.(s)

Additional numbers attached?  Yes  No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Stanley W. Sokoloff

Internal Address:

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN

Street Address: 12400 Wilshire Boulevard, 7<sup>th</sup> Floor

City: Los Angeles State: CA

ZIP: 90025

6. Total number of applications and registrations involved: 1

7. Total fee (37 CFR 3.41) ..... \$ 40.00

Enclosed

Deficiency of fees authorized to be charged to deposit account

8. Deposit account number:

02-2666

(Attach duplicate copy of this page if paying by deposit account)

02/28/2003 TBI/AZI 00000098 75390737

01 FC:6521

40.00 CP

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Stanley W. Sokoloff

Name of Person Signing

Signature

February 5, 2003

Date

Total number of pages comprising cover sheet: \_\_\_\_\_

**ASSIGNMENT**

WHEREAS, OTSUKA PHARMACEUTICAL CO., LTD. a Japanese corporation, having a principal address at 2-9, Kanda Tsukasa-cho, Chiyoda-ku, Tokyo, Japan (hereinafter referred to as "Assignor"), has interested to use the following trademark and has filed the following application indicating such intention, but has not yet filed allegations of use under §§1(c) or 1(d) of the Trademark Act:

<u>Mark</u>	<u>Serial No.</u>	<u>Filing Date</u>
RLP	75/390737	November 17, 1997

WHEREAS, Assignor is assigning the mark in the above-identified application as part of the entire business to which the mark pertains as required by 15U.S.C. §1060;

WHEREAS, JAPAN IMMUNORESEARCH LABORATORIES, CO., LTD., a Japanese corporation, having a principal address at 351-1, Nishiyokote-machi, Takasaki, Gunma, Japan (hereinafter referred to as "Assignee"), is desirous of acquiring said service mark and the pending intent-to-use application.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee all right, title and interest in and to said trademark and said intent-to-use application therefor, together with the goodwill of the business symbolized by said trademark and application to register same.

OTSUKA PHARMACEUTICAL CO., LTD.  
(Assignor)

Date: November 12, 2001

By: 

Name: Kazuhiro Tomita

Title: Executive Director on Board

## CONFIRMATION of BUSINESS ASSIGNMENT for RLP


This is to confirm the Business assignment relating to the diagnostics for determination of the level of remnant like particular in serum in human body (hereinafter referred to as "RLP business") from Otsuka Pharmaceutical Co., Ltd., having a principal office at 2-9, Kanda Tsukasa-cho, Chiyoda-ku, Tokyo, Japan (hereinafter referred to as "Otsuka") to Japan Immunoresearch Laboratories Co., Ltd., having a principal office at 351-1, Nishiyokote-machi, Takasaki, Gunma, Japan (hereinafter referred to as "Jimro").

Since RLP business in Japan was assigned from Otsuka to Jimro on March 15, 1993 and Jimro has been engaging in the research and development works for getting marketing approval from US FDA and consequently Jimro got such marketing approval for RLP diagnostic kit for the diagnosis of familial hyperlipoproteinemia and hepatic hyperlipidemia in August 2000.

Considering these circumstances in the USA Otsuka and Jimro hereby agree that RLP business in USA shall be handled by Jimro and also agree to assign the US trademark application Serial No. 75/390737 RLP under name of Otsuka shall be assigned to Jimro.

November 12, 2001

November 14, 2001



Kazuhiro Tomita  
Executive Director on Board  
Otsuka Pharmaceutical Co., Ltd.



Masakazu Adachi  
President  
Japan Immunoresearch  
Laboratories Co., Ltd.